Dakota Wealth Management Reduces Position in Stryker Corporation $SYK

Dakota Wealth Management reduced its position in shares of Stryker Corporation (NYSE:SYK) by 17.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,889 shares of the medical technology company’s stock after selling 2,266 shares during the period. Dakota Wealth Management’s holdings in Stryker were worth $3,830,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Trust Point Inc. grew its holdings in shares of Stryker by 5.8% during the fourth quarter. Trust Point Inc. now owns 1,509 shares of the medical technology company’s stock worth $530,000 after purchasing an additional 83 shares during the last quarter. Stephens Consulting LLC increased its position in shares of Stryker by 9.6% during the fourth quarter. Stephens Consulting LLC now owns 1,141 shares of the medical technology company’s stock worth $401,000 after purchasing an additional 100 shares in the last quarter. CoreCap Advisors LLC lifted its holdings in shares of Stryker by 0.8% in the 4th quarter. CoreCap Advisors LLC now owns 10,474 shares of the medical technology company’s stock valued at $3,681,000 after purchasing an additional 87 shares during the last quarter. Kathmere Capital Management LLC boosted its position in shares of Stryker by 18.4% in the 4th quarter. Kathmere Capital Management LLC now owns 1,062 shares of the medical technology company’s stock valued at $373,000 after purchasing an additional 165 shares during the period. Finally, Signal Advisors Wealth LLC boosted its position in shares of Stryker by 28.0% in the 4th quarter. Signal Advisors Wealth LLC now owns 6,743 shares of the medical technology company’s stock valued at $2,370,000 after purchasing an additional 1,473 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Down 1.6%

NYSE:SYK opened at $327.49 on Friday. Stryker Corporation has a 12-month low of $324.93 and a 12-month high of $404.87. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. The stock’s 50 day simple moving average is $360.17 and its 200-day simple moving average is $363.90. The firm has a market cap of $125.42 billion, a P/E ratio of 38.99, a PEG ratio of 1.94 and a beta of 0.85.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, topping the consensus estimate of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The firm had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. During the same period last year, the company earned $4.01 earnings per share. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. Equities analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Tuesday, March 31st. Stryker’s dividend payout ratio (DPR) is 41.90%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on SYK shares. Truist Financial lowered their target price on shares of Stryker from $400.00 to $392.00 and set a “hold” rating on the stock in a research report on Thursday, December 18th. BTIG Research upped their price target on shares of Stryker from $410.00 to $412.00 and gave the company a “buy” rating in a research report on Friday, January 30th. The Goldman Sachs Group set a $399.00 price objective on shares of Stryker in a research report on Friday, January 9th. Needham & Company LLC lifted their price objective on shares of Stryker from $448.00 to $454.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Finally, Sanford C. Bernstein upped their target price on shares of Stryker from $450.00 to $465.00 and gave the company an “outperform” rating in a report on Friday, January 9th. Fourteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $427.50.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares in the company, valued at $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 5.90% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.